Sanofi: presents treatments for MS
(CercleFinance.com) - Sanofi will present new data at the 9th joint ECTRIMS-ACTRIMS meeting evaluating three experimental treatments for multiple sclerosis (MS).
New findings for the bioactive tolebrutinib, the company's investigational oral Bruton's tyrosine kinase (BTK) inhibitor, reinforce the ability of this near-term candidate to reach the central nervous system (CNS) to target latent neuroinflammation.
In addition, Sanofi will present data from frexalimab, the new investigational second-generation anti-CD40L antibody, and SAR443820, the first investigational oral brain-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
New findings for the bioactive tolebrutinib, the company's investigational oral Bruton's tyrosine kinase (BTK) inhibitor, reinforce the ability of this near-term candidate to reach the central nervous system (CNS) to target latent neuroinflammation.
In addition, Sanofi will present data from frexalimab, the new investigational second-generation anti-CD40L antibody, and SAR443820, the first investigational oral brain-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor.
Copyright (c) 2023 CercleFinance.com. All rights reserved.